OLD Republic International Corp continued to hold its position in Pfizer, Inc. (NYSE:PFE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,538,500 shares of the biopharmaceutical company’s stock at the close of the second quarter. Pfizer accounts for approximately 1.7% of OLD Republic International Corp’s investment portfolio, making the stock its 16th biggest holding. OLD Republic International Corp owned 0.09% of Pfizer worth $51,678,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Shine Investment Advisory Services Inc. bought a new position in Pfizer in the second quarter worth about $102,000. D. Scott Neal Inc. lifted its holdings in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC bought a new position in Pfizer in the first quarter worth about $121,000. Cascade Investment Advisors Inc. lifted its holdings in Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after acquiring an additional 2,200 shares during the last quarter. Finally, Perennial Advisors LLC lifted its holdings in Pfizer by 7.9% in the second quarter. Perennial Advisors LLC now owns 5,132 shares of the biopharmaceutical company’s stock worth $172,000 after acquiring an additional 376 shares during the last quarter. Institutional investors and hedge funds own 69.36% of the company’s stock.
In other Pfizer news, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $32.70, for a total value of $263,692.80. Following the transaction, the insider now owns 74,506 shares in the company, valued at $2,436,346.20. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the transaction, the insider now owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. In the last 90 days, insiders sold 374,621 shares of company stock worth $12,796,098. 0.06% of the stock is currently owned by company insiders.
Pfizer, Inc. (PFE) opened at $35.36 on Thursday. Pfizer, Inc. has a 12 month low of $30.51 and a 12 month high of $36.78. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56. The company has a market cap of $210,889.83, a P/E ratio of 14.15, a P/E/G ratio of 2.50 and a beta of 1.01.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The business had revenue of $13.17 billion for the quarter, compared to analyst estimates of $13.17 billion. During the same quarter last year, the business earned $0.61 earnings per share. The business’s revenue for the quarter was up .9% on a year-over-year basis. research analysts expect that Pfizer, Inc. will post 2.6 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.62%. Pfizer’s dividend payout ratio (DPR) is 79.01%.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.